TAMPA, Fla. — The Food and Drug Administration has given another possible COVID-19 vaccine fast track designation.
The vaccine, produced by Novavax, will begin phase 3 clinical trials by the end of November.
Fast track designation means it could get regularly approval or emergency authorization faster than normal.
The federal government’s operation Warp Speed is giving Novavax $1.6 billion to run its trials.
The company’s vaccine is made by growing synthetic versions of the coronavirus spike protein in moth cells.
A plant-based compound that boosts immune response is also part of it.
The vaccine joins 4 others that have been fast-tracked.